Abstract:Abstract The low activity and yield of antimicrobial peptides (AMPs) are pressing problems. The improvement of activity and yield through modification and heterologous expression, a potential way to solve the problem, is a research hot-pot. In this work, a new plectasin-derived variant L-type AP138 (AP138L-arg26) was constructed for the study of recombination expression and druggablity. As a result, the total protein concentration of AP138L-arg26 was 3.1 mg/mL in Pichia pastoris X-33 supernatant after 5 days of induction expression in a 5-L fermenter. The recombinant peptide AP138L-arg26 has potential antibacterial activity against selected standard and clinical Gram-positive bacteria (G + , minimum inhibitory concentration (MIC) 2–16 μg/mL) and high stability under different conditions (temperature, pH, ion concentration) and 2 × MIC of AP138L-arg26 could rapidly kill Staphylococcus aureus ( S. aureus ) (> 99.99%) within 1.5 h. It showed a high safety in vivo and in vivo and a long post-antibiotic effect (PAE, 1.91 h) compared with vancomycin (1.2 h). Furthermore, the bactericidal mechanism was revealed from two dimensions related to its disruption of the cell membrane resulting in intracellular potassium leakage (2.5-fold higher than control), and an increase in intracellular adenosine triphosphate (ATP), and reactive oxygen species (ROS), the decrease of lactate dehydrogenase (LDH) and further intervening metabolism in S. aureus . These results indicate that AP138L-arg26 as a new peptide candidate could be used for more in-depth development in the future. Key points • The AP138L-arg26 was expressed in the P. pastoris expression system with high yield • The AP138 L-arg26 showed high stability and safety in vitro and in vivo • The AP138L-arg26 killed S. aureus by affecting cell membranes and metabolism

What problem does this paper attempt to address?

The problems that this paper attempts to solve are the low activity and low yield of antimicrobial peptides (AMPs), especially those of antimicrobial peptides against Staphylococcus aureus (S. aureus). Specifically: 1. **Improve the activity and yield of antimicrobial peptides**: Traditional antimicrobial peptides have problems of insufficient activity and low yield in practical applications, which limit their wide application. This research improves the activity and yield of antimicrobial peptides through modification and heterologous expression methods. 2. **Develop new antimicrobial peptides**: The research aims to develop a new antimicrobial peptide variant AP138L - arg26 to replace traditional antibiotics, especially in the fight against drug - resistant bacteria. AP138L - arg26 is a variant derived from plectasin and has higher antimicrobial activity and stability after modification. 3. **Verify the safety and mechanism of antimicrobial peptides**: In addition to improving activity and yield, the research also focuses on the safety of AP138L - arg26 and its antimicrobial mechanism. Through in vitro and in vivo experiments, the research has verified its highly efficient killing effect on Staphylococcus aureus and revealed its specific mechanism of achieving sterilization by destroying cell membranes and affecting metabolic pathways. ### Summary of main research contents - **Construction and expression**: The researchers constructed a new antimicrobial peptide variant AP138L - arg26 and achieved recombinant expression in Pichia pastoris X - 33. - **Antimicrobial activity test**: The results show that AP138L - arg26 has significant antimicrobial activity against a variety of standard and clinically isolated Gram - positive bacteria (G+), with a minimum inhibitory concentration (MIC) of 2–16 µg/mL. - **Stability test**: AP138L - arg26 shows high stability under different conditions (temperature, pH value, ion concentration). - **Safety assessment**: In vitro and in vivo experiments indicate that AP138L - arg26 has high safety. - **Sterilization mechanism**: The research shows that AP138L - arg26 achieves highly efficient sterilization effects by destroying cell membranes, causing potassium ion leakage, increasing intracellular ATP and reactive oxygen species (ROS), and reducing lactate dehydrogenase (LDH) activity. These results indicate that AP138L - arg26, as a new antimicrobial peptide candidate, has the potential for further development, especially in the fight against drug - resistant bacteria.

Expression and characterization of the new antimicrobial peptide AP138L-arg26 anti Staphylococcus aureus